Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

TS Expression Explored in ALK-positive NSCLC

August 1st 2012

Expression levels of thymidylate synthase may help point the way to new treatment options for patients with ALK-positive NSCLC, including combination therapy.

The PARP Inhibitors: Down But Not Out

July 31st 2012

In spite of the setbacks, researchers remain hopeful that a better understanding of the mechanism of action for PARP inhibitors will lead to effective treatment of a wide variety of cancers.

Putting Key Developments in Two Tumor Types in Focus

July 27th 2012

As the molecular understanding of breast cancer continues to evolve, the search for treatment targets based upon tumor subtypes and gene expression patterns is intensifying.

Sipuleucel-T Studies Support Earlier Use, Reveal Potential Biomarker

July 25th 2012

Research presented at ASCO 2012 examined the expanded use of sipuleucel-T, as well as methods to determine which patients might benefit the most from the therapy.

Dr. Rotkowitz Defines Personalized Medicine

July 23rd 2012

Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, Defines Personalized Medicine

Dr. Anthony on Targeted Therapy Associated Diarrhea

July 16th 2012

Dr. Lowell Anthony from the University of Kentucky Markey Cancer Center on Targeted Therapy Associated Diarrhea.

FDA Approves Cetuximab Plus FOLFIRI for Metastatic Colorectal Cancer

July 10th 2012

The FDA has approved cetuximab in combination with the FOLFIRI regimen as a first-line treatment for patients with mCRC who express EGFR and wild-type KRAS mutations.

Five Questions for Hans-Peter Gerber, PhD

July 10th 2012

Hans-Peter Gerber has been building a program to develop novel biotherapeutics for oncology, including antibody-drug conjugates, at the Pfizer Oncology Research Unit in Pearl River, New York.

Dr. Kris on the Combination of Targeted Therapies

July 6th 2012

Dr. Mark Kris, from Memorial Sloan-Kettering Cancer Center, on the Combination of Molecularly Targeted Therapies.

University of Chicago Comprehensive Cancer Center: Innovation in Research

July 6th 2012

For nearly 40 years, the University of Chicago Comprehensive Cancer Center has enjoyed a reputation for excellence and innovation.

Antibody-Drug Conjugates: Guided Missiles Deployed Against Cancerous Cells

July 5th 2012

Antibodies directed against tumor cell antigens or overexpressed proteins are currently the fastest-growing class of targeted cancer therapeutics.

Case-Based Discussion: Sequencing Prostate Cancer Therapy

July 3rd 2012

Case-based discussion on sequencing prostate cancer therapies for a 72-year-old man with a metastatic adenocarcinoma with small-cell components, a PSA score of 80, and a Gleason score of 10.

Diarrhea Less Severe With Molecularly Targeted Agents Than With Standard Chemotherapy

June 30th 2012

Recent evidence shows that some of the newer molecularly targeted therapies can cause diarrhea, which can lead to dose reductions and alterations.

Targeted Therapies Safer for Heart Than Anthracyclines

June 30th 2012

Although molecularly targeted agents can cause cardiac damage, it appears to be reversible and related to cellular dysfunction, as distinct from agents such as anthracyclines that cause cellular death and irreversible cardiac dysfunction.

Dr. Kirkman on the Combination of PX-866 and Docetaxel

June 27th 2012

Dr. Robert Kirkman, the CEO of Oncothyreon, on the Combination of PX-866 and Docetaxel

Dr. Hauschild Discusses the Dabrafenib BREAK-3 Trial

June 26th 2012

Dr. Axel Hauschild, from University Hospital, Schleswig-Holstein, Germany, Discusses the BREAK-3 Trial That Investigated the BRAF Inhibitor Dabrafenib.

Mutations Pass From Primary to Recurrent Endometrial Cancer

June 26th 2012

Most recurrent endometrial tumors have the same PI3K/Akt mutation profile as found in the primary tumor.

Unexpected Mutations Doom Therapy for Glioblastoma

June 25th 2012

Unexpected target mutations likely doomed a proven therapeutic approach to lung cancer in a test against glioblastoma.

Dr. Sandler Discusses the Tivantinib Mechanism of Action

June 25th 2012

Dr. Alan Sandler, from the Oregon Health & Science University, Discusses the Tivantinib Mechanism of Action

Targeting Non-Mutant EGFR: Genetic and Clinical Biomarkers May Help Validate Use of Inhibitors

June 25th 2012

A recent study suggests patients may be selected for therapy based on the number of EGFR gene copies, and evaluated for clinical benefit based on the severity of the rash that often develops.